Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (Dare) is dated April 1, 2019. The company is an emerging growth company incorporated in Delaware, headquartered in San Diego, California. The report addresses a specific regulatory event regarding its listing status on The Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance required for regulatory compliance:
- Stock Price: The closing bid price of Dare's common stock was $1.00 per share or greater for 10 consecutive business days (March 18, 2019, to March 29, 2019).
Material Changes
The primary material change reported is the resolution of a prior non-compliance issue with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- Previous Status: Dare was previously non-compliant because its closing bid price was less than $1.00 for 30 consecutive business days preceding November 30, 2018.
- Current Status: Dare regained compliance as of April 1, 2019, and the matter is now closed.
Guidance, Outlook, and Management Commentary
Management has issued a press release (Exhibit 99.1) confirming the regained compliance. Additionally, the company has released a corporate presentation (Exhibit 99.2) dated April 1, 2019, detailing the company and its product candidates. Dare intends to utilize this presentation in meetings with investors and securities analysts commencing on the filing date. No specific financial guidance or forward-looking projections regarding revenue or earnings are provided in this text.
Investor Verification Checklist
- Verify the current trading status of Dare's common stock on Nasdaq to ensure continued compliance with the minimum bid price rule.
- Review the attached press release (Exhibit 99.1) for any additional context on the stock price recovery.
- Examine the corporate presentation (Exhibit 99.2) for updates on product candidates and strategic direction.
- Consult the company's most recent 10-K or 10-Q filings for comprehensive financial data, as this 8-K does not contain financial statements.